Documents - Marketing authorisation medicines for human use
48 documents Marketing authorisation medicines for human use
- Date
- Relevance
-
Terms and conditions for package fee and reduced fee for copy DCP application - human products
The term package fee entails that a group of products (each with an individual RVG number) is only billed once at the tariff ...
-
MEB 6: Labelling of pharmaceutical products
The presentation of the primary and secondary packaging of a medicinal product are determining factors in the recognition of a ...
-
MEB 5: Package leaflet of pharmaceutical products
This policy document explains the policy regarding the package leaflet of pharmaceutical products in the Netherlands. Download ...
-
MEB 21: Statement of ‘abbreviated indications’ on OTC medicinal product packaging
Directive 2001/83/EC discusses European regulations on labelling. In accordance with Article 54(n), the outer packaging of ...
-
Question and answer document pertaining to variations for medicines for human use
-
Questions and answers about Compassionate Use Programme
In the MEB49 policy document, we set out the policy for the Compassionate Use Programme (CUP). We have provided answers to ...
-
Questions and answers about the timeslot tool
For a number of procedures for human medicines (including herbal medicines and homeopathic medicines), the MEB has a tool ...
-
Question and answer document concerning changes not covered by the Variation Regulation 1234/2008 (as amended by Regulation 712/2012)
-
MEB 13: Nomenclature of pharmaceutical products
This document describes the requirements which the marketing authorisation holder has to fulfil when submitting a proposal for a ...
-
Declaration by the applicant pertaining to the application for a Duplex marketing authorisation (Model I) - Duplex with supplementary conditions